Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 TrialGlobe Newswire•09/09/2026•08:000 ShareWhiz InsightsGenerateNo content available.
